A novel strategy to overcome drug resistance in cancer

克服癌症耐药性的新策略

基本信息

  • 批准号:
    10319166
  • 负责人:
  • 金额:
    $ 23.87万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-01 至 2027-02-28
  • 项目状态:
    未结题

项目摘要

ABSTRACT The major obstacle to successful cancer therapy is the rapid development of drug resistance. While targeted therapies often extend overall survival in the subset of patients with sensitizing mutations, their effects are short-lived. Patients who initially respond to these drugs generally develop resistance within a few months. Single-cell sequencing of tumors has revealed significant genetic heterogeneity; tumor cells without the sensitizing mutation survive therapy and re-populate the tumor. At the same time, compensatory epigenetic and genetic changes relieve dependence on the targeted pathway, also contributing to resistance. There is thus a critical unmet need for new therapeutic strategies capable of providing more robust cancer control. A robust system continues to function even when an individual component fails. In the context of drug development, a robust therapy would produce parallel, redundant anti-cancer effects, each of which is sufficient to inhibit tumor growth. One approach to achieving such redundancy is to embrace the pleiotropic actions of natural compounds. Endogenous signaling molecules produce coordinated and complex responses by targeting multiple signaling nodes in parallel. For example, endogenous sphingolipids exhibit potent tumor suppressor activity by producing multifaceted and incompletely characterized changes in signaling pathways that trigger proliferative arrest in normal cells and death in cancer cells. SH-BC-893 (893), a synthetic sphingolipid with improved drug properties, retains the anti-neoplastic activity of these natural compounds. In a rigorous, genetically-engineered mouse model for aggressive prostate cancer, 893 reduces autochthonous tumor growth by 82%. In a related subcutaneous isograft model, 893 produces tumor regressions in >50% of mice. 893 is also effective against patient-derived prostate tumor organoids that are resistant to standard-of- care therapies. The major argument against pleiotropic agents has been that toxicity will be unacceptably amplified relative to more specific drugs. However, natural sphingolipids induce quiescence in normal cells as part of an adaptive, homeostatic response to stress. Indeed, 893 does not cause organ toxicity or disrupt the proliferation of normal cells in the bone marrow or intestinal crypts even after 3 months of treatment with the anti-neoplastic dose. Normal cells are more resistant to 893, but 893’s pharmacokinetic properties also likely contribute to its safety margin. Our preliminary data showing that 893 engages multiple, high-value oncology targets results raise the possibility that 893 will be less susceptible to drug resistance and could overcome resistance to FDA-approved therapies. This proposal will test this provocative hypothesis. The expected results would have a significant positive impact by changing thinking in the field and providing a novel therapeutic strategy that would be effective in patients with late-stage, lethal prostate cancers.
抽象的 癌症治疗成功的主要障碍是耐药性的迅速发展。虽然有针对性 治疗通常可以延长具有敏化突变的患者的总体生存期,其效果是 短暂的。最初对这些药物有反应的患者通常会在几个月内产生耐药性。 肿瘤的单细胞测序揭示了显着的遗传异质性;肿瘤细胞没有 敏化突变在治疗中存活并重新填充肿瘤。同时,补偿性表观遗传 基因变化减轻了对目标途径的依赖,也有助于抵抗。有 因此,对能够提供更强有力的癌症控制的新治疗策略的迫切需求尚未得到满足。一个 即使单个组件发生故障,强大的系统也能继续运行。在毒品的背景下 发展过程中,强有力的疗法会产生并行的、多余的抗癌作用,其中每一个作用都是 足以抑制肿瘤生长。实现这种冗余的一种方法是采用多效性 天然化合物的作用。内源信号分子产生协调且复杂的反应 通过并行定位多个信令节点。例如,内源性鞘脂表现出强效的肿瘤作用 通过在信号通路中产生多方面且不完全表征的变化来抑制活性 触发正常细胞的增殖停滞和癌细胞的死亡。 SH-BC-893 (893),一种合成 鞘脂具有改善的药物特性,保留了这些天然化合物的抗肿瘤活性。在一个 第893章 肿瘤生长82%。第893章 50%以上的肿瘤消退 老鼠。第893章 护理疗法。反对多效剂的主要论点是毒性将是不可接受的 相对于更具体的药物而言被放大。然而,天然鞘脂会导致正常细胞静止 对压力的适应性、稳态反应的一部分。事实上,893 不会引起器官毒性或破坏 即使治疗 3 个月后,骨髓或肠隐窝中的正常细胞仍会增殖 抗肿瘤剂量。正常细胞对 893 的抵抗力更强,但 893 的药代动力学特性也可能 有助于其安全边际。我们的初步数据显示 893 涉及多种高价值肿瘤学 第893章 893 对 FDA 批准的疗法产生耐药性。该提案将检验这一具有争议性的假设。预期结果 通过改变该领域的思维并提供新的治疗方法将产生重大的积极影响 该策略对晚期致命性前列腺癌患者有效。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Aimee L Edinger其他文献

Aimee L Edinger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Aimee L Edinger', 18)}}的其他基金

A novel strategy to overcome drug resistance in cancer
克服癌症耐药性的新策略
  • 批准号:
    10609389
  • 财政年份:
    2021
  • 资助金额:
    $ 23.87万
  • 项目类别:
Defining the role of macropinocytosis in solid tumor growth and therapeutic resistance
定义巨胞饮作用在实体瘤生长和治疗耐药中的作用
  • 批准号:
    10368053
  • 财政年份:
    2020
  • 资助金额:
    $ 23.87万
  • 项目类别:
Defining the role of macropinocytosis in solid tumor growth and therapeutic resistance
定义巨胞饮作用在实体瘤生长和治疗耐药中的作用
  • 批准号:
    10640820
  • 财政年份:
    2020
  • 资助金额:
    $ 23.87万
  • 项目类别:
Identification of the anti-neoplastic target of bioactive FTY720 analogs
生物活性 FTY720 类似物抗肿瘤靶点的鉴定
  • 批准号:
    8568587
  • 财政年份:
    2013
  • 资助金额:
    $ 23.87万
  • 项目类别:
Identification of the anti-neoplastic target of bioactive FTY720 analogs
生物活性 FTY720 类似物抗肿瘤靶点的鉴定
  • 批准号:
    8710117
  • 财政年份:
    2013
  • 资助金额:
    $ 23.87万
  • 项目类别:
Effects of sphingolipids on nutrient transporter expression and bioenergetics
鞘脂对营养转运蛋白表达和生物能学的影响
  • 批准号:
    8541863
  • 财政年份:
    2010
  • 资助金额:
    $ 23.87万
  • 项目类别:
Effects of sphingolipids on nutrient transporter expression and bioenergetics
鞘脂对营养转运蛋白表达和生物能学的影响
  • 批准号:
    7769039
  • 财政年份:
    2010
  • 资助金额:
    $ 23.87万
  • 项目类别:
Effects of sphingolipids on nutrient transporter expression and bioenergetics
鞘脂对营养转运蛋白表达和生物能学的影响
  • 批准号:
    8146063
  • 财政年份:
    2010
  • 资助金额:
    $ 23.87万
  • 项目类别:
Effects of sphingolipids on nutrient transporter expression and bioenergetics
鞘脂对营养转运蛋白表达和生物能学的影响
  • 批准号:
    8317814
  • 财政年份:
    2010
  • 资助金额:
    $ 23.87万
  • 项目类别:
Effects of sphingolipids on nutrient transporter expression and bioenergetics
鞘脂对营养转运蛋白表达和生物能学的影响
  • 批准号:
    8730169
  • 财政年份:
    2010
  • 资助金额:
    $ 23.87万
  • 项目类别:

相似海外基金

台湾の小中学校におけるジェンダー平等教育の実践-教員が「ally」となるためにはー
台湾中小学性别平等教育实践——让教师成为“盟友”
  • 批准号:
    24K05716
  • 财政年份:
    2024
  • 资助金额:
    $ 23.87万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allostatic Load in Latino Youth (ALLY) study: The Role of Discrimination and Environmental Racism
拉丁裔青年的均衡负荷 (ALLY) 研究:歧视和环境种族主义的作用
  • 批准号:
    10677710
  • 财政年份:
    2022
  • 资助金额:
    $ 23.87万
  • 项目类别:
Turning an enemy into an ally: Privacy In Machine Learning (Pri-ML)
化敌为友:机器学习中的隐私 (Pri-ML)
  • 批准号:
    DGECR-2022-00376
  • 财政年份:
    2022
  • 资助金额:
    $ 23.87万
  • 项目类别:
    Discovery Launch Supplement
Turning an enemy into an ally: Privacy In Machine Learning (Pri-ML)
化敌为友:机器学习中的隐私 (Pri-ML)
  • 批准号:
    RGPIN-2022-03721
  • 财政年份:
    2022
  • 资助金额:
    $ 23.87万
  • 项目类别:
    Discovery Grants Program - Individual
Animals, Lifeways and Lifeworlds in Yup'ik Archaeology (ALLY): Subsistence, Technologies, and Communities of Change
尤皮克考古学中的动物、生活方式和生命世界(ALLY):生存、技术和变革社区
  • 批准号:
    AH/N504543/1
  • 财政年份:
    2016
  • 资助金额:
    $ 23.87万
  • 项目类别:
    Research Grant
Marie Duval presents Ally Sloper: the female cartoonist and popular theatre in London 1869-85.
玛丽·杜瓦尔 (Marie Duval) 介绍艾丽·斯洛珀 (Ally Sloper):1869-85 年伦敦的女漫画家和受欢迎的剧院。
  • 批准号:
    AH/M000257/1
  • 财政年份:
    2014
  • 资助金额:
    $ 23.87万
  • 项目类别:
    Research Grant
Development of new function by suppression of martensitic transition in Fe-Pt ally
通过抑制 Fe-Pt 合金中的马氏体转变开发新功能
  • 批准号:
    21860009
  • 财政年份:
    2009
  • 资助金额:
    $ 23.87万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Studies on the biocompatibility of magnesium ally implant materials
镁合金植入材料的生物相容性研究
  • 批准号:
    366590-2008
  • 财政年份:
    2008
  • 资助金额:
    $ 23.87万
  • 项目类别:
    University Undergraduate Student Research Awards
High strength and high conductivity nanoparticle-precipitated copper ally : optimizaiton of thermomechanical processing
高强度和高导电性纳米颗粒沉淀铜合金:热机械加工的优化
  • 批准号:
    15560601
  • 财政年份:
    2003
  • 资助金额:
    $ 23.87万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Fabrication of Integrated Air Valve Chip Using Shape Memory Ally Thin Film
使用形状记忆合金薄膜制造集成气阀芯片
  • 批准号:
    06555072
  • 财政年份:
    1994
  • 资助金额:
    $ 23.87万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了